FibroGen will announce Q1 2025 financial results on May 12, followed by a conference call and webcast.
Quiver AI Summary
FibroGen, Inc. will announce its first quarter 2025 financial results on May 12, 2025, after market close, followed by a conference call at 5:00 PM Eastern Time to discuss the results and provide a business update. Interested parties can join the conference call via a live audio webcast or phone registration, with a replay available afterward on the company's website. FibroGen is a biopharmaceutical company focusing on novel therapies for cancer and anemia, notably having its drug Roxadustat approved in various countries for treating anemia in chronic kidney disease. The company is also developing FG-3246 for metastatic castration-resistant prostate cancer along with an associated biomarker.
Potential Positives
- FibroGen is scheduled to announce its first quarter 2025 financial results, which could provide transparency and insight into the company's performance and future prospects.
- Management will conduct a conference call and webcast presentation to discuss financial results and provide updates, enhancing engagement with the investment community.
- The company has significant product approvals for roxadustat in multiple countries, showcasing its global market presence and regulatory achievements.
- FibroGen is advancing novel therapies, including FG-3246 for metastatic castration-resistant prostate cancer and FG-3180 as a biomarker, indicating ongoing innovation in its pipeline.
Potential Negatives
- Announcement of financial results may indicate a period of scrutiny and potentially disappointing performance if results do not meet market expectations.
- Lack of extensive details on ongoing drug developments raises questions about the company's pipeline and future growth prospects.
- No mention of recent clinical trial results or regulatory updates may imply potential challenges or setbacks in the company's drug development efforts.
FAQ
When will FibroGen announce its first quarter 2025 financial results?
FibroGen will announce its first quarter 2025 financial results on May 12, 2025, after the markets close.
What time is the FibroGen conference call?
The FibroGen conference call will take place at 5:00 PM Eastern Time on May 12, 2025.
How can I access the FibroGen conference call?
Interested parties can access the live audio webcast of the FibroGen conference call through a provided link or by phone registration.
What is Roxadustat and where is it approved?
Roxadustat is a treatment for anemia in chronic kidney disease patients, approved in China, Europe, Japan, and other countries.
What is FibroGen's focus in biopharmaceuticals?
FibroGen focuses on developing novel therapies for cancer biology and anemia, including treatments like FG-3246 for prostate cancer.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FGEN Insider Trading Activity
$FGEN insiders have traded $FGEN stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $FGEN stock by insiders over the last 6 months:
- JAMES A SCHOENECK has made 2 purchases buying 300,000 shares for an estimated $105,040 and 0 sales.
- THANE WETTIG (CEO) purchased 145,000 shares for an estimated $50,663
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FGEN Hedge Fund Activity
We have seen 23 institutional investors add shares of $FGEN stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRIMECAP MANAGEMENT CO/CA/ removed 5,295,101 shares (-53.4%) from their portfolio in Q4 2024, for an estimated $2,803,755
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 2,108,544 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,116,474
- JPMORGAN CHASE & CO removed 1,672,988 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $885,847
- GSA CAPITAL PARTNERS LLP removed 1,095,866 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $580,261
- RENAISSANCE TECHNOLOGIES LLC added 605,572 shares (+80.4%) to their portfolio in Q4 2024, for an estimated $320,650
- MACKENZIE FINANCIAL CORP added 441,083 shares (+416.6%) to their portfolio in Q4 2024, for an estimated $233,553
- SQUAREPOINT OPS LLC added 386,752 shares (+inf%) to their portfolio in Q4 2024, for an estimated $204,785
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call
here
. To access the call by phone, please
register here
, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the
Events & Presentations
page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit
www.fibrogen.com
.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
[email protected]
